Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, potentially offering superior fat loss while preserving lean muscle mass Clinical trials show up to 24% body weight reduction with favourable lean mass retention when combined with resistance training The glucagon component may increase energy expenditure and promote fat oxidation, which could benefit cutting phases Protein intake of 1.6-2.2g per kilogram of body weight becomes even more critical when using retatrutide for body recomposition Retatrutide is not yet approved in the UK but is expected to receive regulatory consideration following Phase 3 trial completion Body Composition Goal Calculator Estimate your protein needs and calorie targets for muscle preservation during fat loss Table of Contents What Is Retatrutide and How Does It Work
In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers
The difference is almost entirely attributable to water and glycogen depletion rather than true fat loss
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications
Table 7: Mean (SE) Change in HbA 1c and Insulin at 6 Months in the Dose-Titration Study in Patients with Type 1 Diabetes for Intent-to-Treat Population In the dose titration study, from mean baseline body weight of 81.5 kg, after randomization there was a mean reduction of 1.33 kg in the SYMLIN treatment group compared to a mean increase of +1.25 kg in the placebo treatment group
Dietary fibre is fundamental to maintaining regular bowel function
